Goldman Sachs raised the firm’s price target on Bristol Myers (BMY) to $57 from $51 and keeps a Neutral rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers upgraded to Buy at BofA on pipeline strength
- Bristol Myers upgraded to Buy from Neutral at BofA
- PayPal, SoundHound, Moderna, Devon, Bristol-Myers: Trending by Analysts
- Midday Fly By: Broadcom slides, pot stocks jump
- Roblox downgraded, Lululemon upgraded: Wall Street’s top analyst calls